Pharmacokinetic studies on Wilfactin®, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 10, 2005, Pages 2219-2227

  Goudemand, Jenny ^a   Scharrer, I ^b   Berntorp, E ^c   Lee, C A ^d   Borel Derlon, A ^e   Stieltjes, N ^f   Caron, C ^a   Scherrmann, J M ^g   Bridey, F ^h   Tellier, Z ^h   Federici, A B ⁱ   Mannucci, P M ⁱ  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d ROYAL FREE HOSPITAL   (United Kingdom)

^e CAEN UNIVERSITY HOSPITAL   (France)

^f Cochin Hospital ^*  (France)

^g HÔPITAL FERNAND WIDAL   (France)

^h Laboratoire Français du Fractionnement LFB   (France)

ⁱ UNIVERSITY OF MILAN   (Italy)

Author keywords

Pharmacokinetic; Severe von Willebrand disease; Viral safety; Von Willebrand factor concentrate

Indexed keywords

BLOOD CLOTTING FACTOR 8; FACTEUR; RISTOCETIN; VON WILLEBRAND FACTOR; WILFACTIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; EUROPE; FEMALE; FRANCE; HUMAN; HYPERTHERMIC THERAPY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS INACTIVATION; VON WILLEBRAND DISEASE;

EID: 28444472737     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01435.x     Document Type: Article

References (30)

1. Mannucci PM. How I treat patients with von Willebrand disease. Blood 2001; 97: 1915-9.
2. Sadler JE, Mannucci PM, Berntorp E, Bochkov N, Boulyjenkov V, Ginsburg D, Meyer D, Peake I, Rodeghiero F, Srivastava A. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000; 84: 160-74.
3. Luban NL. The spectrum of safety: a review of the safety of current hemophilia products. Semin Hematol 2003; 3: 10-5.
4. Foster PA. A perspective on the use of FVIII concentrates and cryoprecipitate prophylactically in surgery or therapeutically in severe bleeds in patients with VWD unresponsive to DDAVP: results of an international study. Thromb Haemost 1995; 74: 1370-8.
5. Chang AC, Rick ME, Pierce LR, Weinstein MJ. Summary of a workshop on potency and dosage of von Willebrand factor concentrates. Haemophilia 1998; 4: 1-6.
6. United Kingdom Haemophilia Centre Doctor's organisation (UKHCDO). Guidelines on the selection and use of therapeutic products to treat haemophilia and other bleeding disorders. Haemophilia 2003; 9: 1-23.
7. Mazurier C, Jorieux S, de Romeuf C, Samor B, Goudemand M. In vitro evaluation of a very-high-purity, solvent/detergent-treatment, von Willebrand factor concentrate. Vox Sang 1991; 61: 1-7.
8. Goudemand J, Mazurier C, Marey A, Caron C, Coupez B, Mizon P, Goudemand M. Clinical and biological evaluation in von Willebrand's disease of a von Willebrand factor concentrate with low factor VIII activity. Br J Haematol 1992; 80: 214-21.
9. The European Agency for the Evaluation of Medicinal Products. Note for Guidance on Plasma-derived Medicinal Products. London, UK: Human Medicines Evaluation Unit, 25 January 2001, CPMP/BWP/269/95 rev.3.
10. Mazurier C, Poulle M, Samor B, Hilbert L, Chtourou S. In vitro study of a triple-secured von Willebrand factor concentrate. Vox Sang 2004; 86: 100-4.
11. Mannucci PM. Venous thromboembolism in von Willebrand's disease. Thromb Haemost 2002; 88: 378-9.
12. Makris M, Colvin B, Gupta V, Shields ML, Smith MP. Venous thrombosis following the use of intermediate purity FVIII concentrates to treat patients with von Willebrand's disease. Thromb Haemost 2002; 88: 387-8.
13. Federici AB, Mazurier C, Berntorp E, Lee CA, Scharrer I, Goudemand J, Lethagen S, Nitu I, Ludwig G, Hilber L, Mannucci PM. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood 2004; 103: 2032-8.
14. Mannucci PM. Recommended protocol for the study of the ex vivo biological effects of virus-inactivated plasma concentrates in patients with von Willebrand disease. The von Willebrand Factor Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis and of the von Willebrand Disease Committee of the World Federation of Hemophilia. Thromb Haemost 1992; 68: 84-7.
15. Pearson TC, Guthrie DL, Simpson J, Chinn S, Barosi G, Ferrant A, Lewis SM, Najean Y. Interpretation of measured red cell mass and plasma volume in adults: Expert panel on Radionuclides of the International Council for Standardization in Haematology. Br J Haematol 1995; 89: 748-56.
16. Menache D, Aronson DL, Darr F, Montgomery RR, Kessler CM, Lusher JM, Phatak PD, Shapiro AD, White GC. Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): estimation of the rate of factor VIIIC synthesis. Br J Haematol 1996; 94: 740-5.
17. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15: 657-80.
18. Meriane F, Zerhouni L, Djeha N, Goudemand M, Mazurier C. Biological effects of S/D-treated, very high purity, von Willebrand factor concentrate in five patients with severe von Willebrand disease. Blood Coagul Fibrinolysis 1993; 4: 1023-9.
19. Menache D. Pharmacokinetics of von Willebrand factor and factor VIII coagulant activity in patients with von Willebrand disease type 3 and type 2. Haemophilia 1998; 4: 44-7.
20. Dobrkovska A, Krzensk U, Chediak JR. Pharmacokinetics, efficacy and safety of Humate-P® in von Willebrand disease. Haemophilia 1998; 4: 33-9.
21. Mannucci PM, Chediak J, Hanna W, Byrnes J, Ledford M, Ewenstein BM, Retzios AD, Kapelan BA, Schwartz RS, Kessler C. and the Alphanate Study Group. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood 2002; 99: 450-6.
22. Kraaijenhagen RA, in't Anker PS, Koopman MMW, Reitsma PH, Prins MH, van den Ende A, Büller HR. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 2000; 83: 5-9.
23. Kamphuisen PW, Eikenboom JC, Bertina RM. Elevated factor VIII levels and the risk of thrombosis. Arterioscler Thromb Vasc Biol 2001; 21: 731-8.
24. O'Donnell J, Mumford AD, Manning RA, Laffan MA. Marked elevation of thrombin generation in patients with elevated FVIII:C and venous thromboembolism. Br J Haematol 2001; 115: 687-91.
25. Legnani C, Cosmi B, Cini M, Frascaro M, Guazzaloca G, Palareti G. High plasma levels of factor VIII and risk of recurrence of venous thromboembolism. Br J Haematol 2004; 124: 504-10.
26. Goudemand J, Negrier C, Ounnoughene N, Sultan Y. Clinical management of patients with von Willebrand disease with a VHP vWF concentrate: the French experience. Haemophilia 1998; 4: 48-52.
27. Federici AB, Baudo F, Caracciolo C, Mancuso G, Mazzucconi MG, Musso R, Schinco PC, Targhetta R, Mannucci PM. Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fandhi®) in the treatment of von Willebrand disease: a retrospective clinical study. Haemophilia 2002; 8: 761-7.
28. Auerswald G, Eberspächer B, Engl W, Güthner C, Koksch M, Kreuz W, Nimtz A, Pindur G, Scheel H, Schreiber JD, Siekmann J, Turecek PL, Wolf HH. Successful treatment of patients with von Willebrand disease using a high-purity double-virus inactivated factor VIII/von Willebrand factor concentrate (Immunate®). Semin Thromb Haemost 2002; 28: 203-13.
29. Lubetsky A, Martinowitz U, Luboshitz J, Kent G, Keller N, Tamarin I, Inbal A. Efficacy and safety of a factor VIII-von Willebrand factor concentrate 8Y: stability, bacteriological safety, pharmacokinetic analysis and clinical experience. Haemophilia 2002; 8: 622-8.
30. Lillicrap D, Poon MC, Walker I, Xie F, Schwartz BA and Members of the Association of Hemophilia Clinic Directors of Canada. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, Haemate-P/Humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost 2002; 87: 224-30.